Patents by Inventor Einar M. Sigurdsson
Einar M. Sigurdsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787854Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.Type: GrantFiled: November 5, 2020Date of Patent: October 17, 2023Assignee: NEW YORK UNIVERSITYInventor: Einar M. Sigurdsson
-
Publication number: 20230203139Abstract: The present disclosure is directed to single domain antibodies that bind to tau and the use of these antibodies for the treatment and diagnosis of tauopathies. The present disclosure is also directed to polynucleotides encoding the tau single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of tauopathies.Type: ApplicationFiled: February 19, 2019Publication date: June 29, 2023Inventor: Einar M. SIGURDSSON
-
Patent number: 11519920Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: October 19, 2020Date of Patent: December 6, 2022Assignee: New York UniversityInventor: Einar M. Sigurdsson
-
Publication number: 20220041697Abstract: The present invention relates to antibody-based molecules that are capable of preferentially and selectively binding to the C-terminal di-phosphorylated {p}Ser396/{p}Ser404 Tau peptide as well as to the {p}Ser404 Tau peptide and the non-phosphorylated Tau peptide, but does not bind to the {p}Ser396 Tau peptide. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other Tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention also have particular utility as prophylactic and therapeutic molecules for the treatment and/or prevention of Alzheimer's disease and related tauopathies.Type: ApplicationFiled: December 10, 2019Publication date: February 10, 2022Inventor: Einar M. SIGURDSSON
-
Publication number: 20220033482Abstract: The present disclosure is directed to single domain antibodies that bind to ?-synuclein and the use of these antibodies for the treatment and diagnosis of ?-synucleinopathies The present disclosure is also directed to polynucleotides encoding the ?-synuclein single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of ?-synucleinopathies.Type: ApplicationFiled: February 19, 2019Publication date: February 3, 2022Inventor: Einar M. SIGURDSSON
-
Publication number: 20210061894Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.Type: ApplicationFiled: November 5, 2020Publication date: March 4, 2021Applicant: New York UniversityInventor: Einar M. Sigurdsson
-
Publication number: 20210055309Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: ApplicationFiled: October 19, 2020Publication date: February 25, 2021Applicant: New York UniversityInventor: Einar M. Sigurdsson
-
Patent number: 10859582Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phosphoserine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: October 4, 2018Date of Patent: December 8, 2020Assignee: New York UniversityInventor: Einar M. Sigurdsson
-
Publication number: 20200190173Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: ApplicationFiled: July 3, 2019Publication date: June 18, 2020Applicant: New York UniversityInventors: Einar M. Sigurdsson, Ayodeji Asuni
-
Publication number: 20190025331Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phosphoserine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: ApplicationFiled: October 4, 2018Publication date: January 24, 2019Applicant: New York UniversityInventor: Einar M. Sigurdsson
-
Patent number: 10132818Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: July 6, 2015Date of Patent: November 20, 2018Assignee: New York UniversityInventor: Einar M. Sigurdsson
-
Publication number: 20180002414Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: ApplicationFiled: August 17, 2017Publication date: January 4, 2018Applicant: New York UniversityInventors: Einar M. Sigurdsson, Ayodeji Asuni
-
Patent number: 9777056Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: GrantFiled: August 24, 2015Date of Patent: October 3, 2017Assignee: New York UniversityInventors: Einar M. Sigurdsson, Ayodeji Asuni
-
Publication number: 20170212131Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: ApplicationFiled: July 6, 2015Publication date: July 27, 2017Applicant: New York UniversityInventor: Einar M. Sigurdsson
-
Patent number: 9700607Abstract: Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.Type: GrantFiled: February 6, 2014Date of Patent: July 11, 2017Assignee: New York UniversityInventors: Thomas Wisniewski, Einar M. Sigurdsson, Jose Alejandro Chabalgoity, Fernando R. Goni, Blas Frangione
-
Publication number: 20170183400Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.Type: ApplicationFiled: January 6, 2017Publication date: June 29, 2017Applicant: New York UniversityInventor: Einar M. Sigurdsson
-
Patent number: 9409146Abstract: Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (A?) or on dialysis of blood or plasma exchange in order to remove A? peptides from the blood circulation, and/or brain or other affected organs.Type: GrantFiled: October 18, 2012Date of Patent: August 9, 2016Assignee: New York UniversityInventors: Blas Frangione, Einar M. Sigurdsson, Thomas Wisniewski, Jorge Ghiso
-
Publication number: 20150368328Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: ApplicationFiled: August 24, 2015Publication date: December 24, 2015Applicant: NEW YORK UNIVERSITYInventors: Einar M. Sigurdsson, Ayodeji Asuni
-
Publication number: 20150044243Abstract: Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.Type: ApplicationFiled: February 6, 2014Publication date: February 12, 2015Applicant: NEW YORK UNIVERSITYInventors: Thomas Wisniewski, Einar M. Sigurdsson, Jose Alejandro Chabalgoity, Fernando R. Goni, Blas Frangione
-
Publication number: 20140302046Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.Type: ApplicationFiled: April 25, 2014Publication date: October 9, 2014Applicant: NEW YORK UNIVERSITYInventor: Einar M. Sigurdsson